Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease
- PMID: 38923034
- DOI: 10.1111/apt.18114
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease
Comment in
-
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.Aliment Pharmacol Ther. 2024 Aug;60(3):427-428. doi: 10.1111/apt.18136. Epub 2024 Jun 24. Aliment Pharmacol Ther. 2024. PMID: 38922940 No abstract available.
Comment on
-
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.Aliment Pharmacol Ther. 2024 Jun;59(11):1312-1334. doi: 10.1111/apt.18006. Epub 2024 Apr 23. Aliment Pharmacol Ther. 2024. PMID: 38651771
References
REFERENCES
-
- Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59:1312–1334.
-
- Turner D, Ricciuto A, Lewis A, D'amico F, Dhaliwal J, Griffiths AM, et al. STRIDE‐II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat‐to‐target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
-
- Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, et al. Limited uptake of ulcerative colitis “treat‐to‐target” recommendations in real‐world practice. J Gastroenterol Hepatol. 2018;33(3):599–607.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources